Therapeutics(31)

  • Novel Antibody Therapeutics Targeting Senescent Cells for Cancer and Fibrotic Disease Treatment (No. T4-2158)

    Senescent cells play a dual role in cancer and fibrosis, where their persistent presence can drive chronic inflammation, tissue remodeling, and disease progression. ... Read more
    Prof Valery Krizhanovsky

    Valery Krizhanovsky

    Faculty of Biology

    19186
  • MMP14 targeting natural antibodies to treat ovarian cancer (No. T4-2152)

    MMP14 is a major antibody target on the tumor cell surface as it is highly expressed on tumor cells and plays a key role in cancer progression and metastasis. Natural occurring autoantibodies targeting MMP14 were isolated from ovarian cancer patients. ... Read more
    Full Professor Irit Sagi

    Irit Sagi

    Faculty of Biology

    17825
  • Novel Combination Therapy For Improved Management of Depression (No. T4-2129)

    A novel combination therapy pairing ketamine with retigabine, an FDA-approved KCNQ channel activator, offers a promising strategy for mood-related disorders. ... Read more
    Full Professor Alon Chen

    Alon Chen

    Faculty of Biology

    6097
  • Modulating Weight Gain and Loss by Understanding the Mechanism of Smoking Related Weight Changes (No. T4-2078)

    A new approach to prevent weight gain during smoking cessation (SCWG) focuses on the gut microbiome and metabolites like dimethylglycine (DMG) and acetylglycine (ACG). ... Read more
    Associate Professor Eran Elinav

    Eran Elinav

    Faculty of Biology

    17357
  • Biosynthetic pathways for producing Psychedelics (No. T4-2077)

    Applying a multitude of enzymes to generate biosynthetic pathways to synthesize different Psychedelics such as DMT, Psilocin, Psilocybin, Peyote related compounds, and so on. ... Read more
    Full Professor Asaph Aharoni

    Asaph Aharoni

    Faculty of Biochemistry

    19433
  • Enhanced Anti-PD-L1 Immunotherapy (No. T4-2059)

    A novel approach for enhancing the efficacy of PD-L1 targeting antibodies by harnessing beneficial FcγR signaling pathways. Strategy involves either (1) Co-administration of PD-L1 targeting antibodies with an FcγRIIB-blocking antibody or ... Read more
    Prof Rony Dahan

    Rony Dahan

    Faculty of Biology

    17039
  • Covalent Chemistry Platform for Diagnostics and Drug Discovery (No. T4-2045)

    CoLDR (Covalent Ligand-Directed Release) chemistry enables site-specific covalent labeling and activation of endogenous proteins using small-molecule covalent ligands. ... Read more
    Senior Scientist Nir London

    Nir London

    Faculty of Chemistry

    6106
  • Safer CAR-T Cell Platform (No. T4-2033)

    A platform for engineering CAR-T cells with enhanced cancer-killing ability and reduced toxicity. By redesigning the transmembrane domain of the CAR using a computational protein design platform, researchers created synthetic receptors that form stable, specific oligomeric structures. ... Read more
    Associate Professor Sarel FLEISHMAN

    Sarel-Jacob Fleishman

    Faculty of Biochemistry

    6124
  • AI-Driven Discovery Platform for Immune Protein Inhibitors (No. T4-2027)

    There is a growing need for innovative strategies to selectively target key drivers of immune-mediated diseases. ... Read more
    Full Professor Rotem Sorek

    Rotem Sorek

    Faculty of Biochemistry

    19381
  • Small Molecules for Treatment of Huntington's Disease and Related Disorders (No. T4-1947)

    A new class of small molecules offers a targeted strategy for treating Huntington’s disease (HD) and related trinucleotide repeat expansion disorders (TREDs). ... Read more
    Full Professor Rivka Dikstein

    Rivka Dikstein

    Faculty of Biochemistry

    6193

Pages

Subscribe to Therapeutics